A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD.

Simon Wan Yau MingJohn Haughney Dermot RyanIain SmallFederico Lavorini Alberto PapiDave SinghDavid M G HalpinJohn R HurstShishir PatelMatthias OchelJanwillem KocksVictoria CarterAntony Hardjojo David J Price

Published in: International journal of chronic obstructive pulmonary disease (2020)

Initiating ICS/LABA treatment of COPD with extrafine-formulation BDP/FF was noninferior in preventing moderate/severe exacerbations compared to FP/SAL and BUD/FF.

Keyphrases

chronic obstructive pulmonary disease
randomized controlled trial
lung function
early onset
high intensity
air pollution
replacement therapy